Table 3 |
|||||||||
|
Estimation of tumor content by segmentation in the CRL-2324 dilution series (data set 3) |
|||||||||
|
Hemizygous loss 18q21.32-q22.3† |
Single copy gain 13q11-q12.3‡ |
CNN LOH 13q21.31-qter§ |
|||||||
|
|
|
|
|||||||
|
Tumor (%)* |
Expected mBAF |
Observed mBAF |
Tumor (%) |
Expected mBAF |
Observed mBAF |
Tumor (%) |
Expected mBAF |
Observed mBAF |
Tumor (%) |
|
|
|||||||||
|
0 |
0.5 |
0.53 |
12 |
0.5 |
0.53 |
15 |
0.5 |
0.53 |
6 |
|
10 (7-12) |
0.53 |
0.53 |
11 |
0.52 |
0.53 |
12 |
0.55 |
0.54 |
7 |
|
14 (10-17) |
0.54 |
0.53 |
12 |
0.53 |
0.53 |
12 |
0.57 |
0.55 |
9 |
|
21 (17-26) |
0.56 |
0.55 |
18 |
0.55 |
0.54 |
16 |
0.6 |
0.58 |
16 |
|
23 (18-28) |
0.56 |
0.6 |
32 |
0.55 |
0.56 |
28 |
0.62 |
0.64 |
28 |
|
30 (24-35) |
0.59 |
0.58 |
27 |
0.57 |
0.55 |
21 |
0.65 |
0.62 |
24 |
|
34 (28-40) |
0.60 |
0.59 |
31 |
0.57 |
0.55 |
23 |
0.67 |
0.64 |
29 |
|
45 (38-51) |
0.65 |
0.61 |
37 |
0.59 |
0.56 |
27 |
0.72 |
0.67 |
33 |
|
47 (40-54) |
0.65 |
0.65 |
46 |
0.6 |
0.57 |
35 |
0.74 |
0.71 |
42 |
|
50 (43-57) |
0.67 |
0.64 |
43 |
0.6 |
0.57 |
30 |
0.75 |
0.7 |
39 |
|
79 (74-83) |
0.83 |
0.84 |
81 |
0.64 |
0.6 |
51 |
0.9 |
0.89 |
77 |
|
100 |
1 |
0.93 |
93 |
0.67 |
0.65 |
88 |
1 |
0.95 |
89 |
|
|
|||||||||
|
*95% confidence interval within parentheses. †Hemizygous loss chr18:54400001-71300000. ‡Single copy gain chr13:16000001-31100000. §Copy number neutral LOH chr13:60500001-114142980. |
|||||||||
|
Staaf et al. Genome Biology 2008 9:R136 doi:10.1186/gb-2008-9-9-r136 |
|||||||||
